1. Home
  2. DBL vs TRDA Comparison

DBL vs TRDA Comparison

Compare DBL & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DoubleLine Opportunistic Credit Fund of Beneficial Interest

DBL

DoubleLine Opportunistic Credit Fund of Beneficial Interest

HOLD

Current Price

$13.75

Market Cap

268.9M

Sector

N/A

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

BUY

Current Price

$4.71

Market Cap

275.3M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
DBL
TRDA
Founded
2011
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
268.9M
275.3M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
DBL
TRDA
Price
$13.75
$4.71
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
★ $19.00
AVG Volume (30 Days)
154.2K
★ 342.0K
Earning Date
01-01-0001
11-05-2026
Dividend Yield
★ 8.67%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $25,421,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$87.90
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$12.94
$4.11
52 Week High
$15.70
$16.45

Technical Indicators

Market Signals
Indicator
DBL
TRDA
Relative Strength Index (RSI) 55.89 35.75
Support Level $12.94 $4.11
Resistance Level $14.45 $7.89
Average True Range (ATR) 0.21 0.42
MACD 0.06 -0.02
Stochastic Oscillator 97.62 34.18

Price Performance

Historical Comparison
DBL
TRDA

About DBL DoubleLine Opportunistic Credit Fund of Beneficial Interest

Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: